Ayana Pharma is a renowned pharmaceutical company specializing in the development of Liposomal Therapeutics for the treatment of cancer. Established in 2012 by Prof. Chezy Barenholz, co-inventor of Doxil® - Doxorubicin-HCl Liposomal Injection, Ayana Pharma has made significant strides in the field of cancer treatment.

Their lead product, LC101 (Doxorubicin-HCl Liposomal Injection), has received FDA approval for the treatment of Ovarian Cancer, Multiple Myeloma, and AIDS-related Kaposi’s Sarcoma. Ayana Pharma has secured an FDA-accredited, cGMP manufacturing facility to support the commercial launch of LC101. They have also entered into a strategic agreement with a top-tier pharma company for the widespread commercialization of LC101 in the U.

S. With an overall market opportunity worth $500 million worldwide, Ayana Pharma faces minimal competition due to the high entry barriers involved in the complex nanotechnology drug industry. Backed by accomplished company leadership, Ayana Pharma continues to push the boundaries of cancer treatment through their innovative Liposomal Therapeutics.

For more information, please visit their website or contact them via phone or email